This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.
Longevity Biotech
Visit WebsiteA ground-breaking therapeutic company that is developing breakthrough peptide technology.
The company is focusing on delivering clinically transformative products that tackle the most challenging aspects of medicine today involving unique Patented Hybridtides® which provide critical enhancements.
Product:
Longevity Biotech Hybridtide®
Platform technology is based on a unique synthetic peptide scaffold that provides critical enhancements and is differentiated compared to other peptide scaffolds. The most important feature of this breakthrough technology is the prospect of oral delivery of Hybridtide-based peptide therapeutics. The company’s goal is to remove the frequent injections required for traditional biologic therapeutics and switch them into pill form.
Subsidiaries
Portfolio
- ProAxsis
- Glycotest
- Cetromed
- PDS Biotechnology
- Vortex Biosciences
- Wanda Health
- Q-Bot
- Sofant Technologies
- PointGrab
- SageTech Medical
- Dname-iT
- Oncocidia
- Ventive
- DeepTech Recycling
- G-Tech Medical
- FOx Biosystems
- EpiBone
- Cytovale
- Longevity Biotech
- QuantalX Neuroscience
- Insight Photonics
- Nanotech Industrial Solutions
- Martlet Capital